Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 1408
- Registration Number
- NCT04068103
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Kaiser Permanente South Bay, Harbor City, California, United States
🇺🇸Springfield Memorial Hospital, Springfield, Illinois, United States
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 120
- Registration Number
- NCT04034173
- Locations
- 🇩🇪
Ludwigs Maximialians University, Munich, Germany
FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC
- Conditions
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 109
- Registration Number
- NCT04034459
- Locations
- 🇩🇪
Klinikum der Universitaet Muenchen, Munich, Germany
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
- Conditions
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 647
- Registration Number
- NCT04031703
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1147
- Registration Number
- NCT04008030
- Locations
- 🇩🇪
Local Institution - 0117, Hamburg, Germany
🇩🇪Local Institution - 0008, Hannover, Germany
🇩🇪Local Institution - 0009, Heidelberg, Germany
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 44
- Registration Number
- NCT04005339
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Washington University School of Medicine- Siteman Cancer Center, Saint Louis, Missouri, United States
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT03977233
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT03970252
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
De-Escalation Therapy for Human Papillomavirus Negative Disease
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 36
- Registration Number
- NCT03944915
- Locations
- 🇺🇸
University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT03929666
- Locations
- 🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.